Home > Medicine > Other > Volume-3 > Issue-5 > Cancer Precision Medicine: Physiological Function of C-MYC as Targeted Molecule

Cancer Precision Medicine: Physiological Function of C-MYC as Targeted Molecule

Call for Papers

Volume-8 | Advancing Multidisciplinary Research and Analysis - Exploring Innovations

Last date : 28-Mar-2024

Best International Journal
Open Access | Peer Reviewed | Best International Journal | Indexing & IF | 24*7 Support | Dedicated Qualified Team | Rapid Publication Process | International Editor, Reviewer Board | Attractive User Interface with Easy Navigation

Journal Type : Open Access

First Update : Within 7 Days after submittion

Submit Paper Online

For Author

Research Area


Cancer Precision Medicine: Physiological Function of C-MYC as Targeted Molecule


Takuma Hayashi | Ikuo Konishi



Takuma Hayashi | Ikuo Konishi "Cancer Precision Medicine: Physiological Function of C-MYC as Targeted Molecule" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-5, August 2019, pp.2564-2568, URL: https://www.ijtsrd.com/papers/ijtsrd28030.pdf

The genome represents a design for creating the body, with each one being different. In cancer genomic medicine, many genes are simultaneously examined using mainly cancer tissues (the oncogene panel test), and gene mutations are revealed. Cancer treatments are then initiated according to each individual’s constitution and medical condition based on gene mutations. A system for cancer genome medical treatment is currently being developed. In the treatment of several cancer types, the “oncogene test with an oncogene companion diagnosis” is already being performed as a standard test using cancer tissue to detect one or several gene mutations. Precision Medicine: discovering unique therapies that treat an individual’s cancer based on the specific abnormalities, i.e. germline or somatic mutations of their tumors. In this paper, we will explain the biological role of C-MYC and emphasize the importance of C-MYC as a target factor in cancer precision medicine. The functional activated C-MYC for cell proliferation and tumorigenesis is potential candidate as anti-oncogenic molecule.

C-MYC, gene expression, precision medicine, hepatocyte, partial hepatectomy


IJTSRD28030
Volume-3 | Issue-5, August 2019
2564-2568
IJTSRD | www.ijtsrd.com | E-ISSN 2456-6470
Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

International Journal of Trend in Scientific Research and Development - IJTSRD having online ISSN 2456-6470. IJTSRD is a leading Open Access, Peer-Reviewed International Journal which provides rapid publication of your research articles and aims to promote the theory and practice along with knowledge sharing between researchers, developers, engineers, students, and practitioners working in and around the world in many areas like Sciences, Technology, Innovation, Engineering, Agriculture, Management and many more and it is recommended by all Universities, review articles and short communications in all subjects. IJTSRD running an International Journal who are proving quality publication of peer reviewed and refereed international journals from diverse fields that emphasizes new research, development and their applications. IJTSRD provides an online access to exchange your research work, technical notes & surveying results among professionals throughout the world in e-journals. IJTSRD is a fastest growing and dynamic professional organization. The aim of this organization is to provide access not only to world class research resources, but through its professionals aim to bring in a significant transformation in the real of open access journals and online publishing.

Thomson Reuters
Google Scholer
Academia.edu

ResearchBib
Scribd.com
archive

PdfSR
issuu
Slideshare

WorldJournalAlerts
Twitter
Linkedin